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Several angiogenic growth factors including fibroblast growth factors 1 and 2 (FGF1 and FGF2) depend on heparan sulphate (HS) for
biological activity. We previously showed that all cellular elements in ovarian tumour tissue synthesised HS but biologically active HS
(i.e. HS capable of binding FGF2 and its receptor) was confined to ovarian tumour endothelium. In this study, we have sought to
explain this observation. Heparan sulphate sulphotransferases 1 and 2 (HS6ST1 and HS6ST2) attach sulphate groups to C-6 of
glucosamine residues in HS that are critical for FGF2 activation. These enzymes were strongly expressed by tumour cells, but only
HS6ST1 was found in endothelial cells. Immunostaining with the 3G10 antibody of tissue sections pretreated with heparinases
indicated that HS proteoglycans were produced by tumour and endothelial cells. These results indicated that, in contrast to the
endothelium, HS produced by tumour cells may be modified by cell-surface heparanase (HPA1) or endosulphatase (SULF). Protein
and RNA analysis revealed that HPA1 was strongly expressed by ovarian tumour cells in eight of ten specimens examined. HSULF-1,
which removes specific 6-O-sulphate groups from HS, was abundant in tumour cells but weakly expressed in the endothelium. If this
enzyme was responsible for the lack of biologically active HS on the tumour cell surface, we would expect exogenous FGF2 binding
to be preserved; we showed previously that this was indeed the case although FGF2 binding was reduced compared to the
endothelium and stroma. Thus, the combined effects of heparanase and HSULF could account for the lack of biologically active HS in
tumour cells rather than deficiencies in the biosynthetic enzymes.
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The extracellular matrix (ECM) is composed of a network of
macromolecules that maintain tissue and cellular architecture.
Heparan sulphate (HS) proteoglycans (HSPGs) are major compo-
nents of the ECM and of cell-surface membranes, and they play
critical roles in regulating the flow of information between cells
and their microenvironment (Blackhall et al, 2001). In addition to
anchoring cells to matrix fibres and maintaining tissue structure,
HSPGs serve at least two additional biological activities. First, the
HS chains of these PGs bind to many growth factors and cytokines
such as fibroblast growth factors (FGFs), vascular endothelial
growth factor and transforming growth factor (Lyon et al, 1997;
Robinson and Stringer, 2001; Ostrovsky et al, 2002, respectively).
This binding confers on the growth factors resistance to
proteolysis and biological stability and provides a reservoir of
growth and migration factors that can be mobilised in accordance
with physiological demand. Second, cell-surface HSPGs act as
mandatory co-receptors, facilitating binding of growth factors to
their cognate high-affinity signal-transducing receptors (reviewed
in Gallagher, 2001; Presta et al, 2005).
Fibroblast growth factor 2 is a potent angiogenic cytokine, which
is dependent on HS for its biological activity (Yayon et al, 1991,
Chang et al, 2000). In a previous study of HSPGs, we showed that
stromal syndecan 1 was an adverse prognostic factor for ovarian
cancer and that syndecan 3 was unusually expressed by the
vasculature (Davies et al, 2004). However, the majority of the
function of the HSPGs is mediated by the structure of the HS
glycosaminoglycan component (Jayson et al, 1998). Therefore, in a
second study, we investigated the relationship between HS, FGF-2
and the signal-transducing receptors in human, advanced-stage,
serous ovarian adenocarcinoma. Using a unique molecular probe,
FR1c-AP, which consisted of a soluble FGF receptor 1 isoform IIIc
covalently linked to an alkaline phosphatase moiety, the distribu-
tion of HS that had the ability to support the formation of an HS/
FGF-2/FR1c-AP complex was determined (Ornitz et al, 1992;
Chang et al, 2000). This may be taken as a surrogate marker for the
distribution of biologically active HS. In ovarian cancer tissue, we
found that this probe bound predominantly to endothelial cells
and stroma but not adenocarcinoma cells (Whitworth et al, 2005).
In the current study, we therefore tested the hypothesis that the
enzymes that sulphate HS, such as the sulphotransferases and the
HS-cell-surface editing enzymes, such as the endosulphatases and
endoheparanase (HPA1), determine the distribution of FGF2-
activating HS.
Heparan sulphate chains are synthesised as a post-translational
modification of specific core proteins in the Golgi by enzymes that
initially polymerise a chain of repeating glucuronic acid (GlcA)
and GlcNAc disaccharides, which are then variously modified by
N- and O-sulphation and hexuronic acid epimerisation, converting
glucuronic acid (GlcA) into iduronic acid (Lindahl et al, 1998).
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sulphated domains (S-domains) that form the principal recogni-
tion sites for heparin/HS-binding proteins.
A key modification of HS is carried out by the small family of
6-O-sulphotransferases (HS6ST) that catalyse the transfer of
sulphate from adenosine 3’-phosphate, 5’-phosphosulphate to
C-6 (exocyclic carbon) of the glucosamine residue in HS, thereby
providing functional groups that are critical to the formation of the
trimolecular signalling complex: FGF2, FGFR and HS (Pye et al,
1998; Robinson et al, 2005; Ai et al, 2006). The S-domains
containing 6-O-sulphate groups can be excised from the HS chain
by cell-surface heparanase (HPA1), a b-endoglycosidase that
releases saccharide fragments from HSPG core proteins. Alter-
natively, the fine structure of HS can be modified by endo-
sulphatases that specifically remove 6-O-sulphate groups from
HS-S-domains (Morimoto-Tomita et al, 2002; Viviano et al, 2004).
This has functional consequences as, in quails, QSULF-1, the avian
homologue of mammalian SULFs, has dual regulatory functions as
a negative regulator of FGF signalling and a positive regulator of
Wnt signalling (Ai et al, 2003; Wang et al, 2004)
Heparanase mRNA expression has been investigated in a wide
variety of human tumours (reviewed in Simizu et al, 2004).
Kodama et al (2003) examined heparanase RNA expression by
RT–PCR in five borderline and 31 malignant epithelial ovarian
tumours. Heparanase mRNA expression was present in 16 of 31
malignant epithelial ovarian tumours. In contrast, in the five
borderline epithelial ovarian tumours, heparanase mRNA was not
detected.
In the current study, we have investigated why biologically
active HS is largely restricted to the ovarian tumour endothelium.
The data suggest that tumour cells synthesise HS, but its binding
properties may be modified by SULF action. Moreover, the pattern
of expression of heparanase reveals the potential for localised
degradation of tumour-associated HS, and release of active HS
saccharide-growth factor complexes that could enhance the
malignant phenotype.
MATERIALS AND METHODS
Tissue samples
Tumours from 10 patients with serous ovarian carcinomas were
investigated; these were a mixture of well, moderately and poorly
differentiated tumours. Two normal ovaries were also examined.
These were taken from consenting patients, under the ethical
permission of South Manchester Research Ethics Committee.
Riboprobe preparation
Specific riboprobes for HS6ST1, HS6ST2, HPA1 and HSULF-1 were
prepared by amplifying gene-specific fragments, identified using
the NCBI Blast programmes, from normal ovarian RNA using the
primers as follows:
HS6ST1 forward 50-AAAGATATCATGGTTGAGCGCCGC-30 and
reverse 50-CTCGCGGACCGGGAAGTAG-30, HS6ST2 forward 50-
GAATTCGGCCAGGCGAAAGCGTC-30 and reverse 50-GTCGACCG
CCATTTCTCTACACTG-30, HPA1 forward 50-TTCGATCCCAA
GAAGGAATCAAC-30 and reverse 50-GTAGTGATGCCATGTAACT
GAATC-30, HSULF-1 forward 50-GGATCCCCTTCCACGCTCTGG
CCGATTG-30 and reverse 50-GGATCCATCCAACAGTCAAAT
CACTTGCCCAAAT-30.
These were cloned into the pSPT19 vector (Roche, Mannheim,
Germany) and the sequence was verified. The vector was
linearised, rendered RNAase-free by phenol/chloroform/isoamyl
alcohol purification and used as a template for in vitro
transcription of digoxigenin-labelled antisense or sense (control)
riboprobes using a SP6/T7 transcription kit (Roche).
ISH method
Tissue sections were dewaxed and rehydrated, denaturated with
0.2 M HCl for 20min and then digested with proteinase K
(5mgml
 1)a t3 7 1C for 30min. Slides were hybridised with the
anti-sense probe or sense probe (negative control) at concentra-
tions of 1–2mgml
 1 in hybridisation buffer (Sigma-Aldrich,
Gillingham, UK). After hybridisation, washes and incubation with
anti-digoxigenin antibody and visualisation were carried out using
NBT/BCIP (Roche) according to the manufacturer’s instructions.
Sections were fixed, mounted and examined with an Olympus
BX51 light microscope (Olympus, Southall, UK) using a  40 plan
neofluar, 1.35 NA, oil immersion objective lens. Visualisation was
carried out utilising a Progress C14 camera (Jenoptik, Jena,
Germany) via Adobe PhotoShop 7.
Streptavidin ABC/HRP Immunohistochemistry
Tissue sections were dewaxed and rehydrated. Antigen retrieval
was performed in citrate buffer (pH6), using a microwave oven.
For 3G10 staining only, sections were pre-treated with heparinases
I and II (Grampian Enzymes, Orkney, UK) at a total of 5mUml
 1
in 50mM sodium acetate, 0.5mM calcium acetate (pH 7.0), for 4h
at 371C, replenishing after 2h. To demonstrate the specificity of
3G10 binding, a negative control section was included in which the
heparinases I and II digestion step had been omitted. Endogenous
peroxidase activity was blocked by incubation in 0.8% H2O2 in
methanol for 10min. A blocking solution of 10% goat serum in
TBS was applied for 10min. Sections were incubated overnight at
41C with either anti-HS monoclonal antibody 10E4 (Seikagaku
Corporation, Tokyo, Japan) at a dilution of 1:200 (5mgml
 1 final
concentration), anti D-HS monoclonal antibody 3G10 (Seikagaku
Corporation) at a dilution of 1:250 (4mgml
 1 final concentration),
or anti-HPA1 monoclonal antibody (Insight Biopharmaceuticals,
Rehovot, Israel) at a dilution of 1:60 (670mgml
 1 final
concentration). An equivalent concentration of non-immune
mouse serum was used as a negative control (DAKO, Kyoto,
Japan). Sections were incubated with biotinylated rabbit anti-
mouse antibody (1:400; 2ngml
 1 final concentration; DAKO),
and with peroxidase-labelled streptavidin (DAKO). Colour was
developed using 3,3’-diaminobenzidine (Sigma-Aldrich, USA).
Counterstaining was performed with Gill’s haematoxylin. Samples
were evaluated by microscopy and semiquantitatively analysed for
heparanase expression (intense, moderate or absent staining).
RESULTS
We have used two in situ techniques to investigate the restricted
distribution of biologically active HS to the tumour endothelium;
the first question we addressed was whether there was evidence
that HS synthesis occurred in tumours. We know that the
molecular probe used to detect biologically active HS has an
absolute requirement for the presence of 6-O-sulphate groups (Pye
et al, 1998) and, therefore, we examined the distribution of
the enzymes that catalyse the attachment of that moiety, the
HS-6-O-sulphotransferases.
In situ hybridisation locates HS6ST1 and HS6ST2 mRNA
Specific digoxigenin-labelled riboprobes for HS6ST1 and HS6ST2
mRNA were generated and used to investigate ten serous
carcinomas and two normal ovaries. Our ability to study normal
ovarian epithelium was compromised by the poor preservation of
cellular architecture. Figure 1A shows HS6ST1 mRNA to be present
in ovarian cancer and endothelial cells, but absent in stroma; all 10
tumours stained with similar intensities. Figure 1B shows HS6ST2
RNA to be present in ovarian cancer cells, but absent in endothelial
cells and stroma and again all 10 tumours stained with similar
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higher levels in tumour than in the normal ovaries examined
(Figure 1A and B, inset).
We extended these studies by examining the distribution of the
mRNA for 2-O-sulphotransferase and this closely mirrored that
seen with the HS6ST2 mRNA, again suggesting that sulphated HS
was made by ovarian cancer cells (data not shown).
HS staining
In our previous study (Whitworth et al, 2005), which showed that
biologically active HS was expressed by the endothelium (inferred
by the binding of the FR1c-AP probe), the implication was that
HS6ST1 would be confined to the endothelium. However, the
above results contradict that hypothesis. Therefore, we carried out
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Figure 1 (A) HS6ST1 ISH shows RNA to be present in ovary tumour and endothelial cells, but absent in stroma and normal ovary (inset). (B) HS6ST2
ISH shows RNA to be present in ovary tumour cells, but absent in endothelial cells, stroma and normal ovary (inset). (C) 10E4, an anti-HS monoclonal
antibody was used to demonstrate that intact HS chains were only present on endothelial cells in ovarian tumours. (D) 3G10 antibody was used to detect
the HS stubs that remain after heparinase digestion. A negative control shows 3G10 staining to be negative without prior heparinase digestion (inset). (E)
Heparanase ISH shows RNA to be present in ovary tumour cells, but absent in endothelial cells and stroma. (F) Heparanase IHC shows protein to be
present in ovary tumour cells, but absent in endothelial cells and stroma. (G) Heparanase IHC on normal human ovary shows protein to be present at a low
level in most cells. (H) HSULF-1 ISH shows RNA to be present in ovary tumour cells, but absent in endothelial cells, stroma and normal ovary (inset). Each
scale bar represents 400mm.
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expressed by the ovarian cancer cells.
The same 10 serous carcinomas and 2 normal ovaries were
examined for the presence of HS using IHC. Figure 1C shows 10E4
staining, which indicated that intact sulphated HS chains were only
present on endothelial cells in ovarian tumours. However Figure 1D
shows 3G10 antibody staining, which detects the HS stubs that
remain on the PG core protein after heparinase depolymerisation.
The inset picture shows that 3G10 does not stain when the
heparinase digestion step is omitted. With both 10E4 and 3G10, all
10 tumours stained with similar intensity. These experiments
showed that carcinoma cells strongly bind to 3G10, suggesting that
HSPGs were made by tumour cells, whereas the HS was
subsequently degraded or modified to eliminate the 10E4 epitope.
Investigation of heparanase (HPA1) mRNA and protein
expression
We have shown that the HS6ST1 and 2 and HS2-OST biosynthetic
enzyme RNA, essential for biologically active HS, were expressed by
ovarian cancer cells although the HS 10E4 epitope, often used as a
marker of HS, was not present on the cell surface. To investigate this
further, we hypothesised that heparanase was present and may be
responsible for the lack of 10E4 reactivity. A specific digoxigenin-
labelled riboprobe for HPA1 was generated and used to investigate
our panel of 10 serous carcinomas and two normal ovaries. Figure 1E
shows heparanase RNA to be present in ovarian cancer cells, but
absent in endothelial cells and stroma. Two of the 10 tumour
specimens showed a lower expression of heparanase RNA. Because of
the extensive processing of heparanase, we also used IHC and this
localised HPA1 protein (Figure 1F) to tumour cells, but did not detect
the enzyme in endothelial cells and only at a low level in stroma. All
10 tumours examined showed similar patterns of protein staining. In
normal human ovary, immunohistochemistry showed that hepar-
anase protein was present at a low level in most cells (Figure 1G).
These experiments demonstrate that heparanase was strongly
expressed by ovarian cancer cells, but was virtually absent from
endothelial cells and normal ovarian tissues.
In situ hybridisation locates HSULF-1 mRNA
HSULF-1 is an enzyme that removes 6-O-sulphate residues from
cell-surface HS. Although the heparanase data might account for
the distribution of biologically active HS, another possibility was
that HSULF-1 might be responsible.
A specific digoxigenin-labelled riboprobe for HSULF-1 was
generated and used to investigate ten serous carcinomas and two
normal ovaries. Figure 1H shows HSULF-1 mRNA to be strongly
expressed in ovarian tumour cells, but expressed at a much lower
level in endothelial cells and stroma. The staining intensity was
similar in all 10 tumours examined. HSULF-1 was expressed at
higher levels in tumour than in the normal ovaries examined
(Figure 1H, inset).
DISCUSSION
In previous studies, we showed that stromal syndecan 1 was an
adverse prognostic factor in ovarian cancer and that syndecan 3,
which is usually found on neuronal tissue, was aberrantly
expressed in the tumour vasculature (Davies et al, 2004). In a
further investigation, we used a novel molecular probe, which
demonstrated that endothelial HS was able to support receptor
engagement when FGF2 was present; in other words, HS had the
capacity to activate FGF2 (Whitworth et al, 2005). In this study we
sought to explain the mechanism.
The findings from this study are summarised in Table 1. The HS
epitope recognised by the antibody 10E4 was only detected on
endothelial cells within ovarian tumour sections. Although the
mRNAs of the synthetic enzymes were present in cancer cells, it
was unclear whether HSPGs were expressed on the cell surface. By
treating the tissues with heparinases to degrade cell-surface HS
and then examining the distribution of bound, exogenously added
3G10 antibody, we were able to test whether the HSPG core
proteins were present on the tumour-cell surface. These data
showed widespread binding of the antibody in the tissue sections,
suggesting that in cancer cells as well as in other cell populations
present within the tumour HS-bearing PGs were expressed on the
plasma membrane.
In a previous study (Whitworth et al, 2005), we showed that in
ovarian tumours the distribution of biologically active HS revealed
by the colocalisation of FGF2 and the FGF-receptor probe (FR1c-
AP) was confined to the tumour endothelium. Whereas FGF2
binds to N and 2-O sulphated S-domains in HS, biologically active
S-domains contain 6-O-sulphate moieties (Kan et al, 1993; Lindahl
et al, 1998; Pye et al, 1998). Thus, the difference in binding
requirements for the FR1c-AP probe and exogenous FGF2 is 6-O-
sulphate on glucosamine; by comparing the distribution of the two
probes we can examine the distribution of 6-O-sulphate. This is the
moiety removed by the HSULF enzymes that we show here to be
expressed strongly by tumour cells but weakly by the endothelial
cells. Although our data apparently contradict those of Lai et al
(2003), the differences have most likely arisen because in our study
we determined the patterns of cellular expression of HSULF on
tissue sections rather than PCR analysis of total tumour mRNA.
However, our data also demonstrate that tumour cells and
endothelial cells can be distinguished by their expression of
HPA1; the high levels of this enzyme on tumour cells compared to
its weak expression on the endothelium is likely to contribute to
the differential reactivities of the HS found on the surfaces of these
two cell populations. Thus, the combined effects of HSULF and
HPA1 are probably responsible for the restricted distribution of
biologically active cell-surface HS in ovarian cancer. These
findings indicate that in ovarian tumours, FGF2 does not act
directly on the malignant cells, rather it acts indirectly by
promoting tumour angiogenesis.
Heparanase has been strongly correlated with metastatic
potential in human cancer probably by disrupting the structure
of basement membranes and by releasing HS saccharide growth
factor complexes from the pericellular matrix enabling their
unrestricted access to cell-surface receptors (Elkin et al, 2001). Our
data again reinforce the importance of HS to the malignant
phenotype and highlight the potential therapeutic advantage of
targeting heparanase in human cancer.
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Table 1 Summary of results
Tumour Stroma Endothelium
Endogenous FGF2
a Low Low Moderate
FGF2 binding
a Mild Moderate Moderate–strong
FR1c-AP
a None Weak Moderate–strong
HPA1 +++ +  
HSULF-1 +++ + +
HS6ST1 +++ + +++
HS6ST2 +++ +  
Intact HS (10E4)   +++
HS stubs (3G10) +++ + +++
aFindings of Whitworth et al (2005).
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